Dr. Clay Siegall is an investment magnate and a business executive. With an education background in zoology and genetics, Dr. Siegall has heavily invested in scientific innovation and drug development. Over the years he has involved himself in research and development of cancer drugs. Currently, Dr. Clay Siegall is the co-founder, chairman, president and CEO of the Seattle Genetics.
Dr. Siegall attended the University of Maryland for BS in zoology and the George Washington University for his Ph.D. in genetics. Dr. Siegall got involved in Seattle Genetics from 1998 and has steered the company to be one of the biggest prospects in rigorous research and development several of cancer medicines. Dr. Siegall also serves as a board of director in Alder Biopharmaceuticals, Mirna Therapeutics, and Ultragenyx Pharmaceutical
.Seattle Genetics prospects
Since 1998, Seattle Genetics has involved itself in researching, manipulating, and developing of human antibodies. Its ability to establish effective antibodies lies in their connection to therapy. This strategy has pushed the Seattle Genetics through up and down to become a renowned pharmaceutical company.
Seattle Genetics has a workforce of around 900 staffs and $10 billion market value. In 2016, its sales improved by 46 percent to about $418 million with its share prices increasing from $20 to $66 over five year period. The company’s big ambitions under Dr. Clay Siegall and massive investment in research, as well as marketing, cement the company as being the most significant pharmaceutical in Washington. Furthermore, it expects to increase its team by 200 by the end of this year. One of the latest Seattle Genetics drug is the Adcetris. The testing of Adcetris is underway and is expected to treat Hodgkin Lymphoma, a lymph system cancer. Also, the company has a pipeline of eleven drugs scheduled to be launched soon.
Dr. Clay Siegall aspirations for Seattle Genetics involve marketing of newer drugs in the international market. To this effect, he opened a new company’s office in Switzerland for the region marketing. Also, in February, he made $2 billion bid to acquire commercial rights to market Immunomedics cancer drugs. However, Clay did withdraw the proposal after a court order.
The Seattle Genetics ambitions have seen it spending $376 million on research in 2016. The firm’s primary drugs, Antibody-drug Conjugate and Adcetris are showing a positive result for being commercially viable. Others include 33A for myloid leukemia, 22ME for bladder cancer and LIV1 for breast cancer are in their prime.